Carlo Wilke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5865546/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	1.2	18
2	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	7.6	27
3	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp> : A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	5.3	21
4	Sensory axonal neuropathy in <i>RFC1</i> -disease: tip of the iceberg of broad subclinical multisystemic neurodegeneration. Brain, 2022, 145, e6-e9.	7.6	6
5	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	6.2	4
6	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	2.4	2
7	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
8	Characteristics of serum neurofilament light chain as a biomarker in hereditary spastic paraplegia type 4. Annals of Clinical and Translational Neurology, 2022, 9, 326-338.	3.7	6
9	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
10	Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1. Neurology, 2022, 98, .	1.1	15
11	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.8	36
12	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	2.4	11
13	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
14	Modelling the cascade of biomarker changes in <i>GRN</i> -related frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 494-501.	1.9	27
15	Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia. Annals of Clinical and Translational Neurology, 2021, 8, 1122-1131.	3.7	11
16	Solving unsolved rare neurological diseases—a Solve-RD viewpoint. European Journal of Human Genetics, 2021, 29, 1332-1336.	2.8	4
17	Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases. European Journal of Human Genetics, 2021, 29, 1325-1331.	2.8	49
18	Solving patients with rare diseases through programmatic reanalysis of genome-phenome data. European Journal of Human Genetics, 2021, 29, 1337-1347.	2.8	34

CARLO WILKE

#	Article	IF	CITATIONS
19	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12
20	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
21	Disease-related cortical thinning in presymptomatic granulin mutation carriers. Neurolmage: Clinical, 2021, 29, 102540.	2.7	8
22	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
23	A dataâ€driven disease progression model of fluid biomarkers in genetic FTD. Alzheimer's and Dementia, 2021, 17, .	0.8	0
24	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
25	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Molecular Medicine, 2020, 12, e11803.	6.9	73
26	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. Movement Disorders, 2020, 35, 1233-1238.	3.9	22
27	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	5.3	19
28	NfL and pNfH are increased in Friedreich's ataxia. Journal of Neurology, 2020, 267, 1420-1430.	3.6	17
29	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	2.4	26
30	Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1556-1564.	2.3	32
31	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
32	The motor band sign in ALS: presentations and frequencies in a consecutive series of ALS patients. Journal of the Neurological Sciences, 2019, 406, 116440.	0.6	25
33	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. Neurolmage, 2019, 189, 645-654.	4.2	33
34	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	1.9	19
35	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
36	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27

CARLO WILKE

#	Article	IF	CITATIONS
37	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	3.1	47
38	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
39	The wide genetic landscape of clinical frontotemporal dementia: systematic combined sequencing of 121 consecutive subjects. Genetics in Medicine, 2018, 20, 240-249.	2.4	60
40	Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes. Neurobiology of Aging, 2018, 62, 244.e9-244.e13.	3.1	30
41	Biallelic Parkin (PARK2) mutations can cause a bvFTD phenotype without clinically relevant parkinsonism. Parkinsonism and Related Disorders, 2018, 55, 145-147.	2.2	6
42	Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. Journal of Neurology, 2018, 265, 1618-1624.	3.6	58
43	Serum neurofilament light chain is increased in hereditary spastic paraplegias. Annals of Clinical and Translational Neurology, 2018, 5, 876-882.	3.7	26
44	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
45	Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in <i>GRN</i> -Negative Frontotemporal Dementia. Neurodegenerative Diseases, 2017, 17, 83-88.	1.4	23
46	Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1270-1272.	1.9	65
47	Induced pluripotent stem cells (iPSCs) derived from cerebrotendinous xanthomatosis (CTX) patient's fibroblasts carrying a R395S mutation. Stem Cell Research, 2016, 17, 433-436.	0.7	1
48	Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. Journal of Neurology, 2016, 263, 558-574.	3.6	40
49	Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants. Neurobiology of Aging, 2016, 37, 208.e11-208.e17.	3.1	38
50	Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease. Current Alzheimer Research, 2016, 13, 654-662.	1.4	31
51	Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiology of Aging, 2015, 36, 1072-1074.	3.1	34
52	Sensorimotor Recalibration Depends on Attribution of Sensory Prediction Errors to Internal Causes. PLoS ONE, 2013, 8, e54925.	2.5	28
53	The valence of action outcomes modulates the perception of one's actions. Consciousness and Cognition, 2012, 21, 18-29.	1.5	20